Stryker price target raised to $336 from $275 at Bernstein

Bernstein raised the firm’s price target on Stryker to $336 from $275 and keeps an Outperform rating on the shares. The firm notes Stryker’s recent performance has been very strong, and the company is well positioned to drive growth and margin enhancement as medtech markets recover. But the stock is expensive, Bernstein notes.